Diagnosis & Disease Information

Human lungs

Pirfenidone Inhibits MRTF Signaling With an Elusive Antifibrotic Mechanism in IPF

Although treatment of idiopathic pulmonary fibrosis (IPF) with pirfenidone significantly slows the decline in pulmonary function, the antifibrotic mechanism of the agent remains elusive. The underlying pathophysiology of IPF is complex and not well understood, with the disease likely triggered by repetitive microinjuries to the airway and alveolar epithelium. A recent study utilized transcriptomic and…

Calculator and stethoscope

Nintedanib Has Higher Healthcare Utilization Costs Than Pirfenidone in IPF

Researchers reported that nintedanib was associated with higher costs for medications, medical visits, as well as a higher global cost compared with pirfenidone—both drugs used to treat idiopathic pulmonary fibrosis (IPF). These results were published in Respiratory Medicine and Research. IPF is a progressive and ultimately lethal lung disease of unknown cause. The prognosis remains extremely…

Vitamin B3

Pirfenidone May Cause Pellagra-Like Symptoms in IPF

A new study published in ERJ Open Research has reported that pirfenidone, a drug widely used in patients with idiopathic pulmonary fibrosis (IPF), can cause pellagra or pellagra-like symptoms such as photosensitivity and nausea.  Multiple studies have validated the efficacy of pirfenidone in alleviating many of the clinical symptoms of IPF. Although this drug is…

Happy patient and doctor

Improved Survival With Reduced-Dose Antifibrotic Treatment in IPF

A large proportion of patients with idiopathic pulmonary fibrosis (IPF) who receive reduced-dose antifibrotic agents experience improved survival compared with cessation of treatment, according to the results of a retrospective analysis published in the journal Respiratory Medicine. It is well known that IPF is a severe interstitial lung disease for which 2 effective antifibrotic agents—nintedanib and…

Liposome encapsulation

Targeting Pathological Collagen a Promising New Treatment Strategy in IPF

A study reports promising results from a new strategy to target pathological collagen in idiopathic pulmonary fibrosis (IPF) by delivering antifibrotic drugs via penetrating liposomes directly to injured alveoli. The study, published in the Journal of Control Release, determined that the liposomes were able to deliver pirfenidone and dexamethasone to repair and remodel the lung…

IPF

Pirfenidone Also Beneficial in Probable or Possible Idiopathic Pulmonary Fibrosis

Pirfenidone treatment leads to favorable outcomes in patients with probable or possible idiopathic pulmonary fibrosis (IPF), as it does in patients with definitive disease. These findings were reached in a European MultiPartner IPF Registry (EMPIRE) analysis published in PLoS One. Pirfenidone is widely used to treat patients with IPF. However, it is not known whether…

Study Identifies Prognostic Factors in Incidentally Diagnosed IPF Cases

Approximately one-third of patients are diagnosed with idiopathic pulmonary fibrosis (IPF) in Japan either during a routine health checkup or while undergoing an examination for another disease, while experiencing minimal or no respiratory symptoms, according to a new study published in Respiratory Medicine. In spite of being diagnosed at a relatively early stage of disease,…

IPF Phase 2b Monoclonal Antibody Study Terminated

A randomized, double-blind, placebo-controlled phase 2b study was terminated due to adverse events (AEs) and a lack of efficacy of BG00011, an anti-αvβ6 immunoglobulin G1 monoclonal antibody, as therapy for idiopathic pulmonary fibrosis (IPF), according to a study published in the American Journal of Respiratory and Critical Care Medicine. The study was carried out after…

Pharmaceutical research

New Trial Testing Deupirfenidone for IPF Now Starting

A new clinical trial testing the idiopathic pulmonary fibrosis (IPF) drug candidate LYT-100 (deupirfenidone) has been initiated.  “The initiation of this study is supported by substantial clinical data demonstrating favorable safety and tolerability of LYT-100,” Julie Krop, MD, chief medical officer of PureTech, the developers of LYT-100, said in a press release. “We are excited…

Inhaler for spray and powder

Pirfenidone-Loaded Nanoparticles as an Alternate Treatment for IPF

Pirfenidone-loaded chitosan nanoparticles are stable after 6 months, a new study published in the Future Journal of Pharmaceutical Sciences found. The nanoparticles could be used as a better alternative to treat idiopathic pulmonary fibrosis (IPF) since they can enhance the concentration of pirfenidone in deep lung tissues with a single, lower dose. Pirfenidone has already…

Next post in IPF News Briefs